Maravai LifeSciences Holdings, Inc. filings document the formal disclosures of a Nasdaq-listed life sciences operating company with Class A common stock. Form 8-K reports furnish quarterly and annual financial results, including revenue, net loss, adjusted EBITDA and business updates for the TriLink nucleic acid synthesis and Cygnus biologics safety testing operations.
The company’s proxy materials describe annual meeting matters, director elections, independent auditor ratification, executive compensation votes and board governance. Other current reports record leadership succession, board-size and committee changes, equity-award treatment, and restructuring actions classified as exit or disposal activities, including related cost disclosures and risk language.
Maravai LifeSciences reported fourth-quarter and full-year 2025 results showing lower revenue but improved profitability metrics in late 2025. Q4 2025 revenue was $49.9 million, down 11.8% year over year, with a net loss of $63.0 million and slightly positive Adjusted EBITDA of $0.5 million. Full-year 2025 revenue was $185.7 million, down 28.3%, with a net loss of $230.8 million and Adjusted EBITDA of $(31.2) million. TriLink revenue fell sharply due to fewer high-volume CleanCap vaccine orders, while Cygnus revenue grew modestly. For 2026, the company guides to revenue of $200–$210 million and Adjusted EBITDA of $18–$20 million, reflecting expectations for renewed growth and better margins.
Maravai LifeSciences Holdings, Inc. received an amended ownership report from 12 West Capital-related entities. 12 West Capital Management LP and its principal, Joel Ramin, report beneficial ownership of 8,921,335 shares of Class A common stock, representing 6.2% of the class.
The stake is held through 12 West Capital funds, which have rights to dividends and sale proceeds. The percentage is based on 145,022,751 Class A shares outstanding as of October 31, 2025. The filers certify the shares were not acquired to change or influence control of Maravai LifeSciences.
Maravai LifeSciences Holdings, Inc. received an updated ownership disclosure from an investor group filing an amended Schedule 13G. The group reports beneficial ownership of 10,486,451 Class A common shares, representing 7.23% of the class as of the event date.
The filing lists Hudson View entities with sole voting and dispositive power over 4,979,802 shares each, JD Squared entities with 3,000,000 shares each, and individuals including Stuart Feldman with 7,979,802 shares. The group certifies the shares were not acquired to change or influence control of Maravai.
Maravai Lifesciences Holdings, Inc. Executive Vice President & General Manager, Cygnus Technologies, Christine Dolan reported an automatic share withholding related to equity compensation. On 01/15/2026, 28,934 shares of Class A common stock were withheld at $3.69 per share to cover tax obligations arising from the vesting of restricted stock unit awards held by her. After this tax withholding event, she beneficially owned 448,973 shares of Class A common stock directly.
Maravai LifeSciences Holdings, Inc. reported a routine insider tax-withholding transaction by its General Counsel, Kurt Oreshack. On 01/15/2026, 31,902 shares of Class A common stock were withheld at a price of $3.69 per share to cover tax obligations triggered by the vesting of restricted stock units held by the insider. After this withholding, Oreshack beneficially owned 424,967 shares of Class A common stock directly. The transaction reflects share withholding for taxes rather than an open-market sale.
Maravai LifeSciences Holdings, Inc. (MRVI) reported an insider purchase by an officer of the company. On 11/14/2025, the reporting person acquired 4,300 shares of Class A Common Stock at $1.79 per share through the Maravai LifeSciences Holdings, Inc. 2020 Employee Stock Purchase Plan. The transaction was reported as exempt under Rule 16b-3. Following this purchase, the insider beneficially owns 477,907 shares of Class A Common Stock in direct ownership.
Maravai Lifesciences Holdings, Inc. (MRVI) reported an insider purchase by its Chief Executive Officer and director, Bernd Brust. On 11/13/2025, Brust, through The Bernd Brust Management Trust, purchased 216,212 shares of Class A common stock in an open-market transaction coded "P". The weighted average purchase price was $3.25 per share, with individual trade prices ranging from $3.235 to $3.25. Following this transaction, the trust beneficially owned 466,771 shares of Class A common stock held indirectly, and an additional 2,000,000 shares were listed as held directly.
Maravai LifeSciences Holdings (MRVI) reported insider purchases on Form 4 by CEO and Director Bernd Brust. The filing shows two open‑market buys of Class A common stock: 157,201 shares on 11/11/2025 at a weighted average price of $3.24 and 93,358 shares on 11/12/2025 at a weighted average price of $3.21, executed through The Bernd Brust Management Trust.
Following these transactions, the table lists 250,559 shares indirectly owned via the trust and 2,000,000 shares directly owned. Prices reflect weighted averages across multiple trades within the disclosed ranges.
Maravai LifeSciences (MRVI) reported a weaker Q3 2025 as revenue fell to $41.6 million from $69.0 million a year ago, driven by lower Nucleic Acid Production demand. The quarter posted a net loss attributable to MRVI of $25.6 million (basic and diluted loss per share $0.18) with a loss from operations of $41.0 million.
Year to date, revenue was $135.9 million versus $202.6 million in 2024, and the operating loss reached $156.5 million. Results include a $42.9 million goodwill impairment taken earlier in 2025 and a Q3 $7.4 million restructuring charge tied to a plan that reduces the workforce by about 25% and narrows facilities.
By segment in Q3, Nucleic Acid Production delivered $25.4 million and Biologics Safety Testing $16.3 million. Cash and cash equivalents were $243.6 million at September 30, down from $322.4 million at year end, as operating activities used $34.8 million year‑to‑date. The company closed two tuck‑in deals in 2025: Molecular Assemblies assets for $11.2 million and Officinae Bio for $15.1 million, adding developed technologies to support RNA/DNA workflows.
Maravai LifeSciences Holdings, Inc. furnished an Item 2.02 report stating it issued a press release announcing financial results for the third quarter of 2025. The press release is included as Exhibit 99.1. The company states this information is furnished, not filed, under the Exchange Act and is not incorporated by reference unless expressly specified.